ClinicalTrials.gg
CompletedNCT04413279Updated Nov 10, 2026Results posted

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

A Phase 4 interventional study of LipiFlow Thermal Pulsation and Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation in Dry Eye Syndromes, sponsored by Eye Surgeons of Indiana. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Eye Surgeons of Indiana · Phase 4, Interventional, and Treatment

How we know

Updated Nov 10, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing dexamethasone in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. Dexamethasone · Dry Eye Syndromes.

Enrollment
14th of 16
20 · median 36
Started
2020
with 4 others
Phase 4
12 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
2 of 16
Eye Surgeons of Indiana

Among the 16 studies testing dexamethasone in Dry Eye Syndromes, this one is the 14th largest by enrollment, is one of 5 that started in 2020, is one of 12 in phase 4, and was the 9th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 16 studies testing dexamethasone in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing dexamethasone in Dry Eye Syndromes as a file.
02

Study summary

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing LipiFlow Thermal Pulsation.

Read the detailed description

This prospective, open-label, single-center, non-randomized, investigator-sponsored clinical study seeks to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation compared to LipiFlow Thermal Pulsation alone. In addition, this study will evaluate the ease of Dextenza insertion and the patient preference for therapy.

After screening a given patient for inclusion and exclusion criteria, and gaining informed consent, each eye will undergo LipiFlow Thermal Pulsation on the same day. The most symptomatic eye will be selected to receive DEXTENZA® insertion on the day of the procedure (study eye), while the other eye will be assigned to a receive a sham punctum dilation (control eye). If there is no obvious symptomatic difference, the right eye will receive the intracanalicular insert. Per patient, the study period will last for approximately 12 weeks after the LipiFlow procedure, consisting of one screening visit, one treatment v4isit and 3 post-procedure follow-up visits (week 1, week 4 and week 12). At week 1, week 4 and week 12, primary and secondary endpoints will be assessed alongside standard-of-care procedures. Adjusting for enrollment period, the study will last a total of approximately 4 months.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient's study eye must meet the following criteria to be eligible for inclusion in the study:

  • 18 years of age or older
  • Evaporative DED with MGD and inflammation
  • Willing and able to comply with clinic visits and study related procedures
  • Willing and able to sign the form

Exclusion criteria

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the study:

  • Patients under the age of 18.
  • Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
  • Active infectious systemic disease
  • Active infectious ocular or extraocular disease
  • Altered nasolacrimal flow of either acquired, induced, or congenital origin
  • to dexamethasone
  • Patient being treated with either topical, oral, or intravenous
  • Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Lipiflow Only Group

    Patients with dry eye disease Lipiflow only

    Procedure: LipiFlow Thermal Pulsation

  • Experimental
    Lipiflow + Dextenza Group

    Patients with dry eye disease Lipiflow + Dextenza

    Drug: Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation

Interventions

  • ProcedureLipiFlow Thermal Pulsation

    To manage patients with dry eye disease secondary to MGD

  • DrugDexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation

    Drug page: DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation

    Also known as: Dextenza

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Meibomian Gland Scores (Expressibility and Quality)

    Meibomian gland expressibility was graded at the slit lamp using the methodology of the pivotal LipiFlow trial. Fifteen glands of the lower eyelid (5 temporal, 5 central, 5 nasal) were each graded on a 0-3 scale (0 = no secretion; 1 = inspissated/toothpaste-like secretion; 2 = cloudy liquid secretion; 3 = clear liquid secretion). Grades were summed to produce a composite Meibomian Gland Expressibility Score ranging from 0 to 45. Higher scores indicate better meibomian gland function. Values shown are the mean score at each study visit.

    Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12

  2. Patient Preference

    As measured by COMTOL Survey

    Time frame: Assessed at Week 12

Secondary outcomes

  1. The Rate of Positive MMP-9

    Meibomian gland inflammation was assessed using the InflammaDry point-of-care immunoassay, which detects elevated matrix metalloproteinase-9 (MMP-9) levels in tear fluid. Results are reported as positive or negative based on a predefined assay threshold. The outcome represents the proportion of eyes testing positive for MMP-9 at each study visit.

    Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit

  2. Mean Change in Ocular Surface Staining

    Corneal fluorescein staining was graded on a 0-3 scale (none to heavy) in 5 corneal regions (superior, inferior, nasal, temporal, central) and summed for a corneal score (range 0-15). Conjunctival lissamine green staining was graded on the same 0-3 scale in 6 conjunctival regions (3 nasal, 3 temporal) and summed for a conjunctival score (range 0-18). Corneal and conjunctival scores were summed to produce a total Ocular Surface Staining Score ranging from 0 to 33. Higher scores indicate greater ocular surface damage (worse outcome). Values shown are the mean score at each study visit.

    Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit

  3. Mean Change in Tear Break-up Time (TBUT)

    Tear break-up time (TBUT) was measured in seconds following fluorescein instillation as the interval between a complete blink and the first appearance of tear film disruption. Higher TBUT values indicate greater tear film stability. Values shown are the mean TBUT at each study visit.

    Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit

  4. Mean Change in Tear Osmolarity (mOsm/L)

    Tear osmolarity was measured using a point-of-care tear osmolarity system and reported in milliosmoles per liter (mOsm/L). Higher values indicate greater tear film hyperosmolarity and ocular surface stress. Values shown are the mean tear osmolarity at each study visit.

    Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit

  5. Mean Change in DEQ-5

    Dry eye symptoms were assessed using the Dry Eye Questionnaire-5 (DEQ-5), a validated patient-reported outcome instrument with scores ranging from 0 to 22. Higher DEQ-5 scores indicate greater severity of dry eye symptoms. The outcome represents the mean change in DEQ-5 score from baseline at each study visit.

    Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit

  6. Mean Change in Best-corrected Visual Acuity (BCVA)

    Best-corrected visual acuity (BCVA) was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and recorded as the number of letters read correctly (range 0 to 100 letters). Higher letter scores indicate better visual acuity. Values shown are the mean BCVA letter score at each study visit.

    Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit

07

Results

Posted Nov 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneLipiflow Only EyeLipiflow + Dextenza Eye
Started2020
Completed1919
Not completed11

Outcome measures

PrimaryChange From Baseline in Meibomian Gland Scores (Expressibility and Quality)

Meibomian gland expressibility was graded at the slit lamp using the methodology of the pivotal LipiFlow trial. Fifteen glands of the lower eyelid (5 temporal, 5 central, 5 nasal) were each graded on a 0-3 scale (0 = no secretion; 1 = inspissated/toothpaste-like secretion; 2 = cloudy liquid secretion; 3 = clear liquid secretion). Grades were summed to produce a composite Meibomian Gland Expressibility Score ranging from 0 to 45. Higher scores indicate better meibomian gland function. Values shown are the mean score at each study visit.

Time frame:
Assessed at Baseline, Week 1, Week 4 and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Meibomian Gland Scores (Expressibility and Quality)
score on a scaleLipiflow Only EyeLipiflow + Dextenza Eye
Baseline16.3 ± 8.013.3 ± 8.1
Week 126.4 ± 11.526.8 ± 12.8
Week 429.7 ± 11.129.3 ± 10.9
Week 1227.3 ± 11.429.8 ± 9.9
PrimaryPatient Preference

As measured by COMTOL Survey

Time frame:
Assessed at Week 12
Reported as:
Count of participants · Participants
Patient Preference
ParticipantsTotal Participants
Preferred Lipiflow and SHAM7
Preferred Lipiflow and DEXTENZA11
Had no preference1
SecondaryThe Rate of Positive MMP-9

Meibomian gland inflammation was assessed using the InflammaDry point-of-care immunoassay, which detects elevated matrix metalloproteinase-9 (MMP-9) levels in tear fluid. Results are reported as positive or negative based on a predefined assay threshold. The outcome represents the proportion of eyes testing positive for MMP-9 at each study visit.

Time frame:
Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Reported as:
Count of units · eyes
The Rate of Positive MMP-9
eyesLipiflow Only EyeLipiflow + Dextenza Eye
Baseline1516
Week 11210
Week 4913
Week 12913
SecondaryMean Change in Ocular Surface Staining

Corneal fluorescein staining was graded on a 0-3 scale (none to heavy) in 5 corneal regions (superior, inferior, nasal, temporal, central) and summed for a corneal score (range 0-15). Conjunctival lissamine green staining was graded on the same 0-3 scale in 6 conjunctival regions (3 nasal, 3 temporal) and summed for a conjunctival score (range 0-18). Corneal and conjunctival scores were summed to produce a total Ocular Surface Staining Score ranging from 0 to 33. Higher scores indicate greater ocular surface damage (worse outcome). Values shown are the mean score at each study visit.

Time frame:
Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Reported as:
Mean · score on a scale
Mean Change in Ocular Surface Staining
score on a scaleLipiflow Only EyeLipiflow + Dextenza Eye
Baseline5.2 ± 4.76.6 ± 6.3
Week 15.6 ± 4.74.5 ± 5.9
Week 43.8 ± 4.33.6 ± 4.6
Week 126.2 ± 6.55.7 ± 5.9
SecondaryMean Change in Tear Break-up Time (TBUT)

Tear break-up time (TBUT) was measured in seconds following fluorescein instillation as the interval between a complete blink and the first appearance of tear film disruption. Higher TBUT values indicate greater tear film stability. Values shown are the mean TBUT at each study visit.

Time frame:
Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Reported as:
Mean · seconds
Mean Change in Tear Break-up Time (TBUT)
secondsLipiflow Only EyeLipiflow + Dextenza Eye
Baseline4.1 ± 3.43.2 ± 2.2
Week 14.6 ± 3.34.9 ± 4.6
Week 46.1 ± 5.56.3 ± 5.8
Week 124.7 ± 3.46.1 ± 4.8
SecondaryMean Change in Tear Osmolarity (mOsm/L)

Tear osmolarity was measured using a point-of-care tear osmolarity system and reported in milliosmoles per liter (mOsm/L). Higher values indicate greater tear film hyperosmolarity and ocular surface stress. Values shown are the mean tear osmolarity at each study visit.

Time frame:
Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Reported as:
Mean · mOsm/L
Mean Change in Tear Osmolarity (mOsm/L)
mOsm/LLipiflow Only EyeLipiflow + Dextenza Eye
Baseline309.1 ± 12.5305 ± 8.8
Week 1313.5 ± 14.8305.1 ± 9.5
Week 4310.5 ± 18.6309.1 ± 18.6
Week 12310.8 ± 18.0307.6 ± 15.5
SecondaryMean Change in DEQ-5

Dry eye symptoms were assessed using the Dry Eye Questionnaire-5 (DEQ-5), a validated patient-reported outcome instrument with scores ranging from 0 to 22. Higher DEQ-5 scores indicate greater severity of dry eye symptoms. The outcome represents the mean change in DEQ-5 score from baseline at each study visit.

Time frame:
Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Reported as:
Mean · score on a scale
Mean Change in DEQ-5
score on a scaleTotal Participants
Baseline12.3 ± 4.4
Week 111.1 ± 4.7
Week 410.3 ± 5.1
Week 129.1 ± 5.9
SecondaryMean Change in Best-corrected Visual Acuity (BCVA)

Best-corrected visual acuity (BCVA) was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and recorded as the number of letters read correctly (range 0 to 100 letters). Higher letter scores indicate better visual acuity. Values shown are the mean BCVA letter score at each study visit.

Time frame:
Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Reported as:
Mean · letters
Mean Change in Best-corrected Visual Acuity (BCVA)
lettersLipiflow Only EyeLipiflow + Dextenza Eye
Baseline85.8 ± 4.485.7 ± 4.1
Week 186.2 ± 3.886.3 ± 5.1
Week 486.3 ± 4.085.9 ± 5.2
Week 1286.0 ± 3.683.9 ± 14.0

Adverse events

Collected over Baseline through Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lipiflow Only Group0/19 (0%)0/19 (0%)0/19 (0%)
Lipiflow + Dextenza Group0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Adults aged 18 years or older with history of evaporative dry eye disease, meibomian gland dysfunction, and clinically significant inflammation as evidenced by ocular surface staining and/or conjunctival hyperemia and/or elevated MMP-9 levels. Exclusion criteria included ocular or nonocular infection, compromised nasolacrimal flow, or concurrent use of or contraindications to corticosteroids

Age, Continuous
Age, Continuous(years)Participants Had Lipiflow in Both Eyes and DEXDENZA in One Eye
Mean59.2 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Participants Had Lipiflow in Both Eyes and DEXDENZA in One Eye
Female18
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants Had Lipiflow in Both Eyes and DEXDENZA in One Eye
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White19
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Participants Had Lipiflow in Both Eyes and DEXDENZA in One Eye
United States20
08

Study locations

1 site
  • Eye Surgeons of Indiana
    Indianapolis, Indiana 46040, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jul 2021, 11 months.

Results were first posted in Nov 2026, 5 years 4 months after primary completion.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 11 months is below that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2020
First posted
Jun 2, 2020
StartActual
Aug 1, 2020
Primary completionActual
Jul 1, 2021
CompletionActual
Jul 1, 2021
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in meibomian gland scoresMeibomian Gland Scores (expressibilityExpressibility and qualityQuality)Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12
  • EditedPatient preference forPreferenceTime frame: Assessed at Week 12
Nov 10, 2026
Documents
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedMean changeChange in MMP-9Ocular Surface StainingTime frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
  • EditedMean changeChange in ocular surface stainingDEQ-5Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
  • EditedMean changeChange in tear breakTear Break-up timeTime (TBUT)Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
  • EditedMean changeChange in tear osmolarityTear Osmolarity (mOsm/L)Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
  • EditedMean changeChange in Best-corrected Visual Acuity (BCVA)Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
  • ChangedBefore Mean change in DEQ-5Now The Rate of Positive MMP-9Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in meibomian gland scoresMeibomian Gland Scores (expressibilityExpressibility and qualityQuality)Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12
    • EditedPatient preference forPreferenceTime frame: Assessed at Week 12
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedMean changeChange in MMP-9Ocular Surface StainingTime frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
    • EditedMean changeChange in ocular surface stainingDEQ-5Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
    • EditedMean changeChange in tear breakTear Break-up timeTime (TBUT)Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
    • EditedMean changeChange in tear osmolarityTear Osmolarity (mOsm/L)Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
    • EditedMean changeChange in Best-corrected Visual Acuity (BCVA)Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
    • ChangedBefore Mean change in DEQ-5Now The Rate of Positive MMP-9Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04413279
Lead sponsor
Eye Surgeons of Indiana
Responsible party
Sponsor
First posted
Jun 2, 2020
Start date
Aug 1, 2020
Primary completion
Jul 1, 2021
Completion
Jul 1, 2021
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Damon Dierker, OD, FAAO
principal investigator · Eye Surgeons of Indiana

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion